title: Prednisone when used as treatment for rejection correlates with poor outcome.
abstract: Since January 1974, 195 of 202 (95%) renal transplants have been performed on blacks at the Howard University Hospital Transplant Center. Hypertension is the most common cause of end-stage renal disease (ESRD) at this center (57%). The immunosuppressive regimens utilized were divided into four eras. The first era (1974-1980) consisted of the prophylactic administration of prednisone, Imuran (AZA), and Minnesota antilymphocyte globulin (MAG) with high prednisone dosage used to treat rejection. One-year, two-year, and five-year patient survival rates were 59% 54%, and 41%, respectively. Graft survival rates for the same period were 53%, 47%, and 36%. In the second era (1980-1983), the same immunoprophylaxis was used but only MAG was used to reverse rejection. One-year and two-year patient survival rates were 90% and 84%. Graft survival rates for the same period were 72% and 64%. When era 1 is compared with era 2, statistically significant improvement in patient survival is evident (P less than 0.005). Graft survival rates are statistically significant for one-year graft survival (P less than 0.05). In the third era (1983-1986), cyclosporine was the principal immunosuppressive agent used along with prednisone. Rejection in this era was treated by adjusting the cyclosporine dose to keep the level between 100 ng to 150 ng per mL and in addition to high prednisone. One-year patient survival and graft survival rates were 83% and 55%, respectively. The fourth era began April 1986 and was initiated because of previous bad experiences with high doses of prednisone to treat rejection in era 1.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.forename: R M
authors.initials: RM
authors.lastname: Toussaint
authors.forename: C O
authors.initials: CO
authors.lastname: Callender
authors.forename: G M
authors.initials: GM
authors.lastname: Dunston
authors.forename: J
authors.initials: J
authors.lastname: Flores
authors.forename: C S
authors.initials: CS
authors.lastname: Walters
authors.forename: D
authors.initials: D
authors.lastname: John
authors.forename: C
authors.initials: C
authors.lastname: Yeager
authors.forename: O
authors.initials: O
authors.lastname: Bond
authors.forename: C
authors.initials: C
authors.lastname: Thompson
authors.forename: J C
authors.initials: JC
authors.lastname: Gear
mesh_terms: D000328:Adult; D005260:Female; D006084:Graft Rejection / Q000187:drug effects*; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D007165:Immunosuppression Therapy; D007676:Kidney Failure, Chronic / Q000601:surgery; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D011241:Prednisone